Jonathan Lim
CEO & Co-Founder, Erasca. On 1 show, 1 appearance, plus 1 compilation re-air not counted. The Shows tab opens the full record on each.
executivefounderinvestorerasca.com ↗
Jonathan Lim is a physician, biotech entrepreneur, and investor who co-founded and serves as CEO of Erasca. He previously led Ignyta until its acquisition by Roche and founded City Hill Ventures.
1shows
1appearances
23statements
6resolved
5supported
0contradicted
83%fully supported
Everything Jonathan Lim said on any show that made the record, most notable first. Each card names its show and opens the statement there.
Lim: 21-day water fast and plant diet cleared advanced lymphoma case
“Here's an example of a forty-two-year-old woman with advanced stage lymphoma. Her CT scan shows that before treatment, her lymph nodes were significantly enlarged. After a 21 day water only fast, you can see that her lymph nodes shrank pretty dramatically. She…”
Erasca claims its ERAS-15 molecular glue outperforms Revolution Medicines' RMC-6236
“And so we actually have our own cyclophiline A molecular glue called ERAS 15 that we just in-licensed, and we're really excited about that with Even higher potency than RMC six two three six”
Lim: Targeting ecDNA could become cancer treatment's fourth revolution
“Well, if we're successful, this would truly represent a fourth revolution in cancer treatment and could be used to compliment existing chemotherapeutic targeted therapy and cancer immunotherapy approaches to erase cancer.”
Biotech funding cycle has shifted away from platforms back to products
“I think the pendulum always swings back and forth between platforms and products and back again. I think we're back in the product cycle”
Lim: Extrachromosomal DNA is found in over 50% of solid tumors
“And this phenomenon is found in more than 50% of all solid tumor types.”
Lim: Nutrition is a critical component of cancer treatment's fifth revolution
“Well, I believe that nutrition is a critical component of the fifth revolution in cancer treatment.”
Lim: Dietary choices can impact health as much as pharmaceutical drugs
“We eat three, sometimes more meals a day, so the foods that we eat can be as impactful to our health as the drugs that we take.”
Halozyme guides to $1 billion in revenue in coming years
“Which now Halozyme is guiding to about a billion dollar in revenue in the next few years.”
Extrachromosomal DNA was an unknown cancer driver until recent discoveries
“Most of the industry didn't even know that this circular chromosomal DNA was a mechanism for driving cancer as well as metastases and recurrence until Paul Michel and others identified this and developed diagnostics to look for it.”
Lim admits skepticism on targeting wild-type RAS until RevMed proved it
“Until RevMed showed that that you could target RAS wild type. I actually was very skeptical that we'd be able to do that. But then when I saw the data, I was just amazed that this was safe and reasonably well tolerated.”
Dr. Jonathan Lim: No single cancer treatment revolution is sufficient alone
“I've outlined five revolutions that give us potential paths to being able to do this, and we've seen some miracles occur. But each one on its own in a vacuum is insufficient.”
Lim: Majority of solid tumor patients do not respond to immunotherapy
“Checkpoint inhibitors have since been approved in multiple solid tumor types outside of metastatic melanoma, and the story holds true where you have a minority of patients that reach that five-year mark, what we call the long tail of survival, but still the ma…”
Lim: Extrachromosomal DNA is the missing link in cancer biology
“I believe the missing link is extra chromosomal DNA or ECDNA, which represents a brand new way in understanding how cancer behaves.”
Dr. Jonathan Lim: Multi-modal personalized therapy will one day erase cancer
“This is what gives me hope that we will be able to one day erase cancer.”
Halozyme had three months of cash and zero VC funding in 2003
“So we had Three months of cash on hand, a company that had zero VC dollars invested.”
Checkpoint inhibitors achieve long-term cures in roughly 20% of patients
“Especially with the checkpoint inhibitors where you see the long tail. So you see about 20% of patients that have long term remission that, that actually turns into cures.”
Lim: ADC Drug Enhertu Has Reached Five Cancer Indications
“Whether it's the, some of the ADCs, like Inheritu, where you see just remarkable long-term survival outcomes OS and PFS with in breast cancer, and now they're in five different indications, including tissue agnostic.”
Lim: U.S. NRAS mutant melanoma patient population is roughly 50,000
“NRAS mutant melanoma, there's about 50,000 patients total in, in the U.S.”
Lim: My Penguin Friend was shot 80% with real penguins
“So about 80% of the movie is shot with real penguins. You can't put penguins in peril though. So 15% is with CGI and then five percent is with puppets or animatronics.”
Lim: Checkpoint inhibitors yield five-year survival for one-third of metastatic melanoma patients
“The data here show you that with checkpoint inhibitors, as many as a third of patients reached that important five-year mark.”
Dr. Jonathan Lim: Cancer causes nearly 10 million deaths globally per year
“Cancer is the second leading cause of death, responsible for nearly ten million deaths globally every year.”
Lim: Over half of cancer patients present with late-stage disease
“More than half of all patients present with advanced or late stage disease.”
Lim: Gleevec approval in 2001 launched precision medicine in oncology
“The second revolution is genomically targeted therapy, which really was birthed in the 19 nineties with the development and subsequent approval of Herceptin for breast cancer and Gleevec, which is an oral therapy for leukemia that was approved in 2001 and esse…”
One line per show, most statements first. The link opens Jonathan's full record on that show: the calibration, argument clarity, speaking style and every statement made there.
| Show | Role there | Eps | Statements | Record | |
|---|---|---|---|---|---|
 a16zLEDGER | CEO & Co-Founder, Erasca | 1 +1 | 23 | 83% 5/6 | full record on the a16z Podcast → |